AbbVie Inc. $ABBV Shares Bought by Fifth Third Bancorp

Fifth Third Bancorp grew its holdings in AbbVie Inc. (NYSE:ABBV) by 0.8% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,491,171 shares of the company’s stock after buying an additional 12,110 shares during the period. AbbVie accounts for approximately 1.1% of Fifth Third Bancorp’s portfolio, making the stock its 15th largest position. Fifth Third Bancorp’s holdings in AbbVie were worth $340,718,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Chelsea Counsel Co. purchased a new position in shares of AbbVie in the 3rd quarter valued at approximately $26,000. Westend Capital Management LLC purchased a new stake in shares of AbbVie during the fourth quarter worth approximately $29,000. Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie during the third quarter worth approximately $31,000. WestEnd Advisors LLC lifted its holdings in shares of AbbVie by 160.4% during the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock worth $32,000 after purchasing an additional 85 shares during the period. Finally, Caitlin John LLC purchased a new position in AbbVie in the 3rd quarter valued at $33,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Multiple sell‑side upgrades and price‑target increases (Bank of America upgraded ABBV to Buy and lifted its PT to $234), signaling renewed analyst conviction around Skyrizi/Rinvoq growth and easing concerns about competitive erosion. Bank of America Upgrades AbbVie
• Positive Sentiment: Additional bullish price‑target moves from major firms — Morgan Stanley raised its PT to $278 (overweight) and Canaccord boosted its PT to $265 — adding upside runway and institutional support for the stock. Canaccord / Morgan Stanley Coverage
• Positive Sentiment: Q1 results and outlook: AbbVie reported ~ $15B revenue in Q1 with strong Skyrizi and Rinvoq sales and raised 2026 adjusted EPS guidance, which underpins the bullish analyst reactions and helps offset Humira declines. AbbVie tops quarterly expectations
• Neutral Sentiment: Corporate PR / ecosystem activity — AbbVie awarded the AbbVie Biotech Innovators Award to RIME Therapeutics (lab space, mentorship) in Canada, boosting long‑term innovation positioning but with limited near‑term financial impact. AbbVie and adMare Announce RIME Therapeutics Award
• Neutral Sentiment: Allergan Aesthetics launched a charitable marketing initiative tied to its Allē program — positive PR and modest commercial support for aesthetics segment but not material for near‑term earnings. Allergan Aesthetics Philanthropy
• Negative Sentiment: Mixed/nuanced earnings signals: while revenue beat and guidance was raised, some metrics and accounting items pulled adjusted EPS dynamics lower in pockets (some data feeds flagged EPS misses or small estimate revisions), creating short‑term volatility. Coverage of earnings nuance
• Negative Sentiment: Minor analyst cuts and insider/positioning signals: Erste trimmed some FY estimates slightly and Quiver summaries show recent insider sales and mixed institutional flows — items investors watch as potential near‑term headwinds. Erste / Institutional Notes

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of analyst reports. Berenberg Bank set a $275.00 price objective on shares of AbbVie in a research report on Tuesday, January 20th. UBS Group lowered their target price on shares of AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a report on Thursday, February 5th. Morgan Stanley boosted their price target on shares of AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research note on Thursday. Wall Street Zen downgraded shares of AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Saturday, April 11th. Finally, Bank of America raised AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price objective on the stock in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and an average target price of $252.90.

AbbVie Trading Up 3.8%

Shares of AbbVie stock opened at $211.66 on Friday. The company has a 50-day moving average of $214.55 and a two-hundred day moving average of $221.60. AbbVie Inc. has a 12-month low of $176.57 and a 12-month high of $244.81. The stock has a market cap of $374.26 billion, a PE ratio of 104.27, a price-to-earnings-growth ratio of 0.73 and a beta of 0.38.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, topping the consensus estimate of $2.59 by $0.06. The business had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a negative return on equity of 911.57% and a net margin of 5.79%.The company’s quarterly revenue was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.46 EPS. On average, sell-side analysts forecast that AbbVie Inc. will post 14.13 EPS for the current fiscal year.

AbbVie Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be given a $1.73 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.3%. AbbVie’s dividend payout ratio (DPR) is currently 293.22%.

Insider Buying and Selling at AbbVie

In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP David Ryan Purdue sold 5,230 shares of the company’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares in the company, valued at $619,868.24. This trade represents a 66.34% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 0.06% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.